NellOne Therapeutics

NellOne Therapeutics is a private, pre-revenue biotech focused on harnessing the NELL1 signaling protein, a key regulator expressed during fetal development, to achieve true tissue regeneration and scarless healing. The company's platform technology aims to control inflammation, recruit stem cells, form new blood vessels, and restore tissue mass and function across a wide range of severe injuries and disorders. While still in the pre-clinical or early development stage, NellOne is targeting significant unmet needs in areas such as viral-induced lung injury, osteoporosis, cartilage, tendon, and muscle repair, with the goal of improving patient outcomes and reducing healthcare system burdens.

Therapeutic platform based on the NELL1 (Neural EGFL Like 1) protein, a matricellular signaling protein that orchestrates tissue regeneration by controlling inflammation, recruiting stem cells, promoting angiogenesis, and restoring tissue structure and function, mimicking fetal-like scarless healing.

NellOne competes in the broad and competitive regenerative medicine field, which includes companies developing stem cell therapies, gene therapies, and other growth factor/protein-based approaches (e.g., using BMPs, FGFs, VEGF). Its differentiation hinges on NELL1's proposed unique dual action as both an anti-inflammatory and a master regulator of holistic tissue regeneration.